b|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

N2 Neuraminidase (NA) Protein with N-Terminal Histidine Tag from Influenza Virus, A/Brisbane/10/2007 (H3N2), Recombinant from Baculovirus

Catalog No. NR-43784

This reagent is the tangible property of the U.S. Government.

For research use only. Not for use in humans.

Contributor and Manufacturer:

BEI Resources

Product Description:

A recombinant form of the N2 Neuraminidase (NA) protein from influenza A virus, A/Brisbane/10/2007 (H3N2) containing an N-terminal histidine tag was produced in Sf9 insect cells using a baculovirus expression vector system and purified by nickel affinity chromatography. The predicted ectodomain coding region of the NA gene was fused to a synthetic gene segment encoding an N-terminal eight-histidine tag followed by a 43 amino acid tetramerization domain from vasodilatorstimulated phosphoprotein (VASP) and a thrombin cleavage site, as described for the 1918 pandemic virus.^{1,2} The predicted protein sequence is shown in Table 1. The fulllength NA precursor protein is 469 residues (GenPept: <u>AFN11835</u>). NR-43784 has a theoretical molecular weight of 51,270 daltons.

Material Provided:

Each vial contains approximately 200 µg of NR-43784 in PBS (pH 7.4). The concentration, expressed as mg/mL, is shown on the Certificate of Analysis.

Packaging/Storage:

NR-43784 was packaged aseptically, in screw-capped plastic cryovials. This product is provided on dry ice and should be stored at -20°C immediately upon arrival. Freeze-thaw cycles should be avoided.

Functional Activity:

NR-43784 was demonstrated to be functionally active based on its ability to cleave the fluorogenic substrate 2'-(4-methylumbelliferyl)- α -D-N-acetylneuraminic acid (4-MUNANA).³

Citation:

Acknowledgment for publications should read "The following reagent was obtained through BEI Resources, NIAID, NIH: N2 Neuraminidase (NA) Protein with N-Terminal Histidine Tag from Influenza Virus, A/Brisbane/10/2007 (H3N2), Recombinant from Baculovirus, NR-43784."

Biosafety Level: 1

Appropriate safety procedures should always be used with this material. Laboratory safety is discussed in the following publication: U.S. Department of Health and Human Services,

Public Health Service, Centers for Disease Control and Prevention, and National Institutes of Health. <u>Biosafety in</u> <u>Microbiological and Biomedical Laboratories</u>. 6th ed. Washington, DC: U.S. Government Printing Office, 2020.

Disclaimers:

You are authorized to use this product for research use only. It is not intended for human use.

Use of this product is subject to the terms and conditions of the BEI Resources Material Transfer Agreement (MTA). The MTA is available on our Web site at <u>www.beiresources.org</u>.

While BEI Resources uses reasonable efforts to include accurate and up-to-date information on this product sheet, neither ATCC[®] nor the U.S. Government makes any warranties or representations as to its accuracy. Citations from scientific literature and patents are provided for informational purposes only. Neither ATCC[®] nor the U.S. Government warrants that such information has been confirmed to be accurate.

This product is sent with the condition that you are responsible for its safe storage, handling, use and disposal. ATCC[®] and the U.S. Government are not liable for any damages or injuries arising from receipt and/or use of this product. While reasonable effort is made to ensure authenticity and reliability of materials on deposit, the U.S. Government, ATCC[®], their suppliers and contributors to BEI Resources are not liable for damages arising from the misidentification or misrepresentation of products.

Use Restrictions:

This material is distributed for internal research, non-commercial purposes only. This material, its product or its derivatives may not be distributed to third parties. Except as performed under a U.S. Government contract, individuals contemplating commercial use of the material, its products or its derivatives must contact the contributor to determine if a license is required. U.S. Government contractors may need a license before first commercial sale.

References:

- Kühnel, K., et al. "The VASP Tetramerization Domain is a Right-Handed Coiled Coil Based on a 15-Residue Repeat." <u>Proc. Natl. Acad. Sci. USA</u> 101 (2004): 17027-17032. PubMed: 15569942.
- Xu, X., et al. "Structural Characterization of the 1918 Influenza Virus H1N1 Neuraminidase." <u>J. Virol.</u> 82 (2008): 10493-10501. PubMed: 18715929.
- Wetherall, N. T., et al. "Evaluation of Neuraminidase Enzyme Assays Using Different Substrates to Measure Susceptibility of Influenza Virus Clinical Isolates to Neuraminidase Inhibitors: Report of the Neuraminidase Inhibitor Susceptibility Network." <u>J. Clin. Microbiol.</u> 41 (2003): 742-750. PubMed: 12574276.

ATCC[®] is a trademark of the American Type Culture Collection.



BEI Resources www.beiresources.org E-mail: <u>contact@beiresources.org</u> Tel: 800-359-7370 Fax: 703-365-2898 **b**|**e**|**i** resources

SUPPORTING INFECTIOUS DISEASE RESEARCH

Figure 1: Predicted Protein Sequence

1	АДРНННННН	HSSSDYSDLQ	RVKQELLEEV	KKELQKVKEE	IIEAFVQELR
51	KRGSLVPRGS	PSRSEF EICP	KLAEYRNWSK	PQCDITGFAP	FSKDNSIRLS
101	AGGDIWVTRE	PYVSCDPDKC	YQFALGQGTT	LNNVHSNDTV	RDRTPYRTLL
151	MNELGVPFHL	GTKQVCIAWS	SSSCHDGKAW	LHVCITGDDK	NATASFIYNG
201	RLVDSIVSWS	KEILRTQESE	CVCINGTCTV	VMTDGSASGK	ADTKILFIEE
251	GKIVHTSTLS	GSAQHVEECS	CYPRYPGVRC	VCRDNWKGSN	RPIVDINIKD
301	HSTVSSYVCS	GLVGDTPRKN	DSSSSSHCLD	PNNEEGGHGV	KGWAFDDGND
351	VWMGRTISEK	SRLGYETFKV	IEGWSNPKSK	LQINRQVIVD	RGNRSGYSGI
401	FSVEGKSCIN	RCFYVELIRG	RKEETEVLWT	SNSIVVFCGT	SGTYGTGSWP
451	DGADINLMPI				

Plasmid-derived amino acids – Residues 1 to 3, 61 to 66

Octa-histidine Tag – Residues 4 to 11

Tetramerization domain – <u>Residues 12 to 54</u> Thrombin cleavage sequence – Residues 55 to 60

NA protein - Residues 67 to 460 [represents amino acid residues 76 to 469 of the native NA protein (GenPept: AFN11835)]